BGMS

#4898
Bio Green Med Solution, Inc. - Common Stock
0.8 6 USD
-0.03%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
0.86
0.86
Intervallo Annuale
0.57
6.70
Variazione giornaliera
-3.37%
Variazione Mensile
-2.27%
Variazione di 6 mesi
-10.06%
Variazione Annuale
-85.67%
Chiusura Precedente
0.8 9
Open
0.8 6
Minimo
0.8 6
Massimo
0.8 6
Volume
3
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Dividendi Documents

2026

Current report, Q3 FY2026
Bio Green Med Solution, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Bio Green Med Solution, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Bio Green Med Solution, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Bio Green Med Solution, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Bio Green Med Solution, Inc. current report, Q1 FY2026
8-K

Bio Green Med Solution, Inc. current report, Q3 FY2015

Full document

Business Context and Reporting Period

This Form 8-K is filed by Cyclacel Pharmaceuticals, Inc. (not Bio Green Med Solution, Inc.) on August 11, 2015. The report announces financial results for the second quarter ended June 30, 2015. The company is a Delaware corporation focused on product candidates, clinical trials, and regulatory filings.

Key Financial Metrics

The filing text references a press release (Exhibit 99.1) containing specific financial results but does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity within the body of this 8-K document.

Material Changes

The document does not contain specific numerical comparisons to prior periods. It notes that the attached press release details the results for the quarter ended June 30, 2015.

Guidance, Outlook, and Risks

The filing includes a standard Forward-Looking Statements section. Management highlights significant risks and uncertainties that could cause actual results to differ materially from expectations, including:

  • Failure of product candidates to demonstrate safety or efficacy in later clinical trials.
  • Difficulties in patient enrollment for clinical trials.
  • Risk of not obtaining regulatory approval to market products.
  • Reliance on outside financing to meet capital requirements.
  • Dependence on collaborative partners for development and commercialization.

A conference call to review financial results was scheduled for August 11, 2015, at 4:30 p.m. Eastern Time.

Investor Verification Checklist

  • Verify the specific revenue, net loss, and cash position figures in the attached Exhibit 99.1 (Press Release), as they are not listed in this summary text.
  • Confirm the company's current cash runway and immediate financing needs given the stated reliance on outside capital.
  • Review the status of ongoing clinical trials and any recent regulatory updates not detailed in this 8-K.
  • Check for any discrepancies between the company name in the metadata request ("Bio Green Med Solution") and the actual registrant ("Cyclacel Pharmaceuticals").